A subsequent retrospective single institution study of 218 patients who underwent primary resection of ACC showed that disease-free survival was better with adjuvant mitotane, although it did not reach statistical significance (HR, 1.76; 95% CI, 0.98–3.16).
← all excerpts
Adjuvant Therapy in Adrenocortical Carcinoma: Reflections and Future Directions.
1
—
—